Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients (PANTHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00798070
Recruitment Status : Active, not recruiting
First Posted : November 25, 2008
Last Update Posted : August 16, 2018
Sponsor:
Collaborators:
Swedish Breast Cancer Group
Austrian Breast & Colorectal Cancer Study Group
German Breast Group
Information provided by (Responsible Party):
Prof Jonas Bergh, Karolinska University Hospital

Brief Summary:

This is an adjuvant, open, prospective, randomized study to compare:

A. Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week, to

B. Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel (FEC→T).

Patients with primary node-positive or high risk lymph node negative breast cancer will be eligible for the study.

The primary objective of the phase 3 study is to compare breast cancer relapse-free survival (BCRFS) between the dtEC→dtT and FE100C→T. To detect a five-year BCRFS difference of 0.710 to 0.790 about 1000 patients per arm will be needed. They will be recruited during four years and followed another two years for breast cancer events.

Secondary objectives are to compare

  1. Distant disease-free survival (DDFS)
  2. Event-free survival and
  3. Overall survival
  4. Health-related quality of life and toxicity analyses according to CTC
  5. Outcome in relation to tumour biological factors and polymorphism patterns

    1. RFS in relation to the Sorlie classes using immunohistochemical markers and/or gene expression profiling comparing A vs B arm
    2. RFS with receptor positive disease (analyzed in the local laboratories as described in the CRFs and also analyzed as continuous variables) in the comparison between the A- and B- arms.
    3. RFS with high and low proliferation, respectively, (analyzed in the local laboratories as described in the CRFs and also analyzed as a continuous variable, or centrally analyzed), in the comparison between the A- and B-arms.
    4. RFS in relation to HER-2/neu status (analyzed in the local laboratories as described in the CRFs) in the primary cancers in the comparison between the A- and B-arms and analyzed whether trastuzumab was given in sequence or concurrently.
    5. RFS analyzed in relation to other molecular markers (e.g. gene expression profiling/ sequencing) in the primary cancers and SNPs signatures in normal DNA (related to toxicities for EC/FEC and docetaxel components, respectively, and given dose levels and outcome in relation to these factors and in relation QoL) to outcome per arm.
    6. RFS analyzed in relation to tumour associated lymphocytes and Y-box binding protein in the comparison between the A- and B-arms.

Tumour tissue will be obtained and stored for studies of prognostication and therapy prediction.

Last patient randomized was September 2011.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: dtEC→dtT Drug: FEC→T Phase 3

Detailed Description:
Are described under the heading "Outcome measures"

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2017 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients
Actual Study Start Date : February 2007
Actual Primary Completion Date : April 2016
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Arm A: dtEC→dtT
Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
Drug: dtEC→dtT
Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
Other Names:
  • Epirubicin
  • Cyclophosphamide
  • Taxotere

Active Comparator: Arm B: FEC→T
Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
Drug: FEC→T
Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
Other Names:
  • Epirubicin
  • Cyclophosphamide
  • Fluorouracil
  • Taxotere




Primary Outcome Measures :
  1. Breast cancer relapse-free survival [ Time Frame: 2 years ]
    Breast cancer recurrence free survival is defined as time from randomization to the first of the events; local-, regional- or distant breast cancer recurrence or death due to breast cancer or last date of follow-up if no event has occurred. This was defined already in the phase 2 protocol (1 Sept 2004).


Secondary Outcome Measures :
  1. Distant disease-free survival [ Time Frame: 2 years ]
    Distant disease free survival is defined as time from randomization to the first of distant metastases or death due to breast cancer.

  2. Event-free survival [ Time Frame: 2 years ]
    Event-free survival is defined as time from randomization to the first of the events breast cancer recurrence (any type), contra-lateral breast cancer, other malignancy or any cause of death.

  3. Overall survival [ Time Frame: 2 years ]
    Overall survival is defined as time from randomization to any death.

  4. Health-related quality of life and toxicity analyses according to CTC [ Time Frame: 2 years ]
  5. Outcome in relation to tumour biological factors and polymorphism patterns [ Time Frame: 2 years ]

    Comparing arm A vs B regarding:

    1. RFS in relation to the Sorlie classes using immunohistochemical markers and/or gene expression profiling comparing A vs B arm;
    2. RFS with receptor positive disease in the comparison between the A- and B arms;
    3. RFS with high and low proliferation, respectively, in the comparison between the A- and B-arms.;
    4. RFS in relation to HER-2/neu status in the primary cancers in the comparison between the A- and B-arms and analyzed whether trastuzumab was given in sequence or concurrently;
    5. RFS analyzed in relation to other molecular markers in the primary cancers and SNPs signatures in normal DNA to outcome per arm;
    6. RFS analyzed in relation to tumour associated lymphocytes and Y-box binding protein in the comparison between the A- and B-arms.

    Description of a to e are more detailed in the protocol, shortened here due to space limitation.


  6. BCRFS in arm A in relation to given dose levels [ Time Frame: 2 years ]
    Breast cancer relapse free survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological proven invasive primary breast cancer, with at least 5 (recommended 10) removed axillary lymph nodes OR negative sentinel node biopsy performed for the node negative cohort. Interval between definitive surgery that includes axillary lymph node dissection and registration must be less than 60 days. Paraffin block from the primary tumour must be retained (not mandatory for Austrian sites). Frozen tumour tissue is strongly recommended to be stored.
  • Receptor negative or positive tumours with 1 or more positive axillary lymph nodes (more than 0.2 mm) OR axillary node negative breast cancers if the primary tumour is larger than 20 mm and receptor negative (Er and Pgr with no receptor content) and being Elston grade III. In Germany high risk node negative breast cancer patients are not eligible until labelling for docetaxel includes node-negative disease.
  • A primary breast cancer patient being 35 years or younger considered suitable for adjuvant chemotherapy (may be receptor negative or positive, HER-2/neu negative or positive, with or without axillary lymph node metastases).
  • Macroscopically and microscopically free margins after radical surgery (no cancer cells at borders of resection).
  • No proven distant metastases (negative chest/pulmonary X-ray, bone scintigram (when clinical signs of skeletal metastases or elevated ALP) supplemented with normal conventional X-ray of hot spots, normal liver function test and haematological function tests; when abnormal values, CT or ultrasound of the liver, patient can be included if no metastases are demonstrated.
  • Female age 18-65.
  • Ambulant patients (ECOG 1 or less).
  • No major cardiovascular morbidity NYHA I or II. (Appendix 3).
  • Written informed consent according to the local ethics committee requirements.
  • Patients of childbearing potential should have a negative pregnancy test within seven days of registration. (In Austria, pregnancy tests have to be repeated monthly during the treatment phase).

Exclusion Criteria:

  • Previous neo-adjuvant treatment.
  • Non-radical surgery (histopathological positive margins).
  • Proven distant metastases.
  • Pregnancy or lactation.
  • Other serious medical condition.
  • Previous or concurrent malignancies at other sites, except basal cell carcinoma and/or squamous cell carcinoma in situ of the skin or cervix. Patients with previous breast cancer (invasive and/or ductal carcinoma in situ) in the other breast without loco-regional (large lung volumes) radiotherapy, without objective findings for relapse, with > 5 years since diagnosis can be included.
  • Abnormal laboratory values precluding the possibility to safely deliver the used cytotoxic agents in the study.
  • Hypersensitivity to drugs formulated in polysorbate 80.
  • Peripheral neuropathy grade ≥2.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00798070


Locations
Show Show 80 study locations
Sponsors and Collaborators
Karolinska University Hospital
Swedish Breast Cancer Group
Austrian Breast & Colorectal Cancer Study Group
German Breast Group
Investigators
Layout table for investigator information
Principal Investigator: Jonas Bergh, MD, PhD Karolinska University Hospital
Additional Information:
Publications of Results:
Other Publications:
Bergh J. Oral presentation, ASCO Annual Meeting 2016.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof Jonas Bergh, MD, PhD, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT00798070    
Other Study ID Numbers: PANTHER SBG2004-1
2007-002061-12 ( EudraCT Number )
ISRCTN39017665 ( Registry Identifier: ISRCTN )
ABCSG25 ( Other Identifier: Austrian Breast and Colorectal Cancer Study Group )
GBG53 ( Other Identifier: German Breast Group )
First Posted: November 25, 2008    Key Record Dates
Last Update Posted: August 16, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Oral presentation at ASCO 4 June 2016 (completed).
Keywords provided by Prof Jonas Bergh, Karolinska University Hospital:
Lymph node positive or high risk lymph node negative breast
cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Fluorouracil
Docetaxel
Epirubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites
Antimetabolites, Antineoplastic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors